Navigation Links
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Date:6/8/2009

About Otelixizumab

Otelixizumab is a novel monoclonal antibody being developed for the treatment of type 1 diabetes and other autoimmune diseases. Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab has not yet been approved for marketing. Data suggest that the antibody may work in patients with type 1 diabetes who have residual beta cells by blocking the function of effector T cells that mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells that are understood to protect against effector T cell damage, thus preserving the beta cells' ability to make insulin.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. The company's pipeline includes its lead candidate, otelixizumab, an anti-CD3 monoclonal antibody partnered with GlaxoSmithKline in Phase 3 development for the treatment of type 1 diabetes; a Phase 1 candidate, MTRX1011A, an anti-CD4 antibody that is being developed in collaboration with Genentech, Inc. for the treatment of autoimmune indications; and two pre-clinical candidates, TRX518 and TRX385, that enhance immune responses and are being evaluated for potential benefit in the treatment of cancer, chronic viral diseases, and as vaccine adjuvants. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerx.com.


'/>"/>
SOURCE TolerRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
9. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
10. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...RNewswire/ -- ,, Reportlinker.com announces th...s catalogue. ,, India Medical Equipment Market...w.reportlinker.com/p0164658/India-Medical-Equipmen...ource=prnewswire&utm_medium=pr&utm_campaig...ical Equipment Market Analysis and Forecasts to 20...
(Date:11/20/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue. ,, Medical Adhesives and Sealants - A US...m/p0164242/Medical-Adhesives-and-Sealants---A-US-M...dium=pr&utm_campaign=prnewswire ,, The us...eminence in medical devices and equipments. Cuttin...
(Date:11/20/2009)...wswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CY... Chief Executive Officer, and Greg Browne, Chief F...Piper Jaffray Health Care Conference in New York o...e conference session and webcast will be audio onl...affray will host a webcast of the presentation liv...
Breaking Medicine Technology:Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 3Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 4Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 6Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 7Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 8Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 9Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 10Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 11Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 12Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 13Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 1Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 2Prize4Life Marks One Year Anniversary of Avi Kremer ALS Treatment Prize 59217 3Costa Atlantica Receives a Perfect Score for Vessel Sanitation 59215 1Costa Atlantica Receives a Perfect Score for Vessel Sanitation 59215 2Costa Atlantica Receives a Perfect Score for Vessel Sanitation 59215 3BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 1BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 2BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 3BioMarins Chief Executive Jean Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times 14411 4
...ostate Cancer Awareness Month, MIAMI and PALM BEA...areness Month, and the CyberKnife Centers of Miami...o treat prostate cancer,without surgery and long t...the most common form of cancer affecting men in th...D., says, "for many cases,that are diagnosed early...
....Y., Sept. 2 The many recent reports,documenting ... (siRNAs) in,animal models of human disease may ac...cts related to the ability of siRNA to activate an...ember 2008 issue (Volume 19,Number 9) of ,Human Ge...ary Ann Liebert, Inc. The paper, which was publish...
Other Medicine Technology:Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy' 2Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy' 3
(Date:11/21/2009)... , Association Discusses Key Provisions of Le...are Reform ,, ST. CHARLES, Ill., Nov. 21 /PRNe...resentatives passing the landmark Affordable Healt... moving key health reform legislation forward, Con... broken health care system. Today, AARP hosted an...
(Date:11/21/2009)... NH based medical credentialin...in its industry to form a partnerhsip with Amerine... This partnership will help to transform quality ... (Vocus) November 21, 2009 -- ISG Group...nounced a new agreement with Amerinet Inc., a lead...
(Date:11/21/2009)... HAPPYneuron,s most popular an...the iPhone and iPod Touch. , ... HAPPYneuron,s most popular and addictive game, Sp...Touch. Split Words is designed to help banish that...litWords iPhone brain game challenges the brain ...
(Date:11/21/2009)... New Haven Dental Group merges...D.S of Branford, CT. , (P...oup, comprised of partners Dr. David Gibson, Dr. D...rrester has just merged their growing practice wit...., , ,When Dr. Pickman decided he wanted to retire...
(Date:11/20/2009)... , Pioneering Neurologist Closer to Understandi.... 20 Dr. Jeremy Schmahm...ool and neurologist at the Massachusetts General H...nted his laboratory,s research on the new field of...MINDlink Foundation. ,, Dr. Schmahmann is an aw...
Breaking Medicine News(10 mins):Health News:AARP Hosts Rep. Bill Foster In Health Care Reform Forum 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:New Haven Dental Group Expands Their Vision 2Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2
...on Inc. (formerly Diagnostic Ultrasound Corporatio...and private practice health care providers, is cel...ogo: http://www.newscom.com/cgi-bin/prnh/20061011...y,s products now used by health care providers in ...
...Prescribing Initiatives Drives Industry-leading Pr...KET, R.I., April 2 If you recently went to your d... soon may be the exception, not the rule. That,s r...quality of health care throughout the state. , ,...
... Treatment with the glitazone class of diabetes d...iabetic macular edema (DME)a common complication t...e April issue of the American Journal of Ophthalm... and Richard Contreras of Southern California Perm...
...-FirstCall/ - Medical International Technology Inc...w.mitinvest.ca ), is pleased to announce that it h...es Patent and Trademark Office for its Needle-Free...world market using a unique low-pressure Needle-fr...
... is in the air, and along with it, tree, flower, a...,s immune system a curve ball. But the April issue...iving magazine uncovers five other surprising a... as foreign bodies and launches an inflammatory re...
...han 1,500 CME Sessions Viewed at www.CardioCareLi... , Boston, MA (PRWEB) Apr...line medical conference for physicians and healthc...which includes video webcasts and a faculty of w...
Other Medicine News:Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Celebrates 25 Years of Improving Patient Care 2Health News:Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Celebrates 25 Years of Improving Patient Care 3Health News:Horizon Blue Cross Blue Shield of New Jersey and CVS Caremark Reach 5.5 Million e-Prescriptions 2Health News:Horizon Blue Cross Blue Shield of New Jersey and CVS Caremark Reach 5.5 Million e-Prescriptions 3Health News:Horizon Blue Cross Blue Shield of New Jersey and CVS Caremark Reach 5.5 Million e-Prescriptions 4Health News:Diabetes drug class linked to vision-threatening complication 2Health News:Medical International Technology Inc. "MIT" Announces that it has received a US Patent for its Needle-Free Jet-Injector 2Health News:Surprising Allergy Triggers May Be Making Your Spring Sniffles Worse 2Health News:CardioCareLive.com, First Ever Online Cardiometabolic Conference, Revolutionizes Continuing Medical Education for Cardiovascular Healthcare Professionals 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: